NEWPHARMA

{
  "events": [
    {
      "kind": "vzw_capital_conversion",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Willem Muyshondt",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Halle",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-11-21",
    "filing_date": "2024-11-19",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "algemene_vergadering",
    "act_date": "2024-06-28",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": {
    "waived": false,
    "firm_kbo": null,
    "firm_name": "Ernst \u0026 Young",
    "ibr_number": null,
    "mission_type": "apport_nature",
    "individual_name": "Emilie Van Callemont"
  },
  "subject_company": {
    "kbo": "0838.666.156",
    "name_full": "NEWPHARMA",
    "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "SA COLRUYT GROUP",
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "expedition",
    "plan financier",
    "bankattest",
    "verslag bedrijfsrevisor"
  ],
  "shareholders_after": [],
  "share_classes_after": []
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": null,
      "delta_eur": 5000000.0,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "numeraire",
      "paid_up_delta_eur": 5000000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "create"
    }
  ],
  "notary": {
    "name": "Tim CARNEWAL",
    "firm_city": null,
    "firm_name": "BERQUIN NOTAIRES",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2023-01-09",
    "filing_date": "2023-01-05",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2022-12-26",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0838.666.156",
    "name_full": "NEWPHARMA",
    "legal_form": "Soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal",
    "procuration"
  ],
  "shareholders_after": [],
  "share_classes_after": []
}